| Literature DB >> 27475642 |
M Bonafede1, N Shi1, R Barron2, X Li3, D B Crittenden3, D Chandler3.
Abstract
UNLABELLED: Patient characteristics contributing to imminent risk for fracture, defined as risk of near-term fracture within the next 12 to 24 months, have not been well defined. In patients without recent fracture, we identified factors predicting imminent risk for vertebral/nonvertebral fracture, including falls, age, comorbidities, and other potential fall risk factors.Entities:
Keywords: Falls; Fractures; Insurance claims; Osteoporosis; Risk factors
Mesh:
Year: 2016 PMID: 27475642 PMCID: PMC4967418 DOI: 10.1007/s11657-016-0280-5
Source DB: PubMed Journal: Arch Osteoporos Impact factor: 2.617
Fig. 1Study periods
Fig. 2Patient counts at key points in patient data set selection
Demographic characteristics
| Fracture group | Control group | |
|---|---|---|
|
|
| |
| Sex, | ||
| Male | 3090 (9.6) | 11,170 (8.5) |
| Female | 29,004 (90.4) | 119,922 (91.5) |
| Mean (SD) age, years | 75.2 (11.7) | 66.4 (10.4) |
| US geographic region, | ||
| Northeast | 4277 (13.3) | 19,929 (15.2) |
| North central | 11,312 (35.2) | 35,462 (27.1) |
| South | 9954 (31.0) | 46,908 (35.8) |
| West | 6484 (20.2) | 28,382 (21.7) |
| Unknown | 67 (0.2) | 411 (0.3) |
| Health plan type, | ||
| Comprehensive | 12,797 (39.9) | 31,613 (24.1) |
| PPO | 12,694 (39.6) | 63,376 (48.3) |
| POS | 1322 (4.1) | 9101 (6.9) |
| HMO | 4220 (13.1) | 19,740 (15.1) |
| Other | 382 (1.2) | 3458 (2.6) |
| Unknown | 679 (2.1) | 3804 (2.9) |
| Index fracture type, | ||
| Hip | 8147 (25.4) | |
| Vertebral | 10,608 (33.1) | |
| Nonhip/nonvertebral | 13,339 (41.6) | |
HMO health maintenance organization, POS point of service, PPO preferred provider organization
Risk factors predictive of imminent risk for fracture (OR > 1) at any fracture site
| Predictor | 12 months prefracture |
| 24 months prefracture |
|
|---|---|---|---|---|
| Demographic and general health characteristics | ||||
| History of falls | 6.67 (6.03–7.37) | <0.0001 | 4.43 (4.09–4.80) | <0.0001 |
| Every additional decade after age 50 years | 2.00 (1.98–2.03) | <0.0001 | 1.97 (1.94–2.00) | <0.0001 |
| Comorbidities | ||||
| CNS disease | 1.41 (1.30–1.52) | <0.0001 | 1.34 (1.25–1.43) | <0.0001 |
| Psychoses | 1.37 (1.26–1.48) | <0.0001 | 1.34 (1.25–1.44) | <0.0001 |
| Alzheimer’s disease | 1.35 (1.22–1.50) | <0.0001 | 1.25 (1.14–1.37) | <0.0001 |
| General health status measures | ||||
| DCIa | ||||
| ≥4 | 1.46 (1.35–1.59) | <0.0001 | 1.49 (1.38–1.62) | <0.0001 |
| 3 | 1.40 (1.31–1.50) | <0.0001 | 1.42 (1.32–1.52) | <0.0001 |
| 2 | 1.26 (1.19–1.32) | <0.0001 | 1.29 (1.22–1.36) | <0.0001 |
| 1 | 1.16 (1.12–1.20) | <0.0001 | 1.17 (1.13–1.22) | <0.0001 |
| Concomitant medications | ||||
| Narcotics | 2.11 (2.05–2.18) | <0.0001 | 1.85 (1.79–1.92) | <0.0001 |
| Antidepressants—SSRIs | 1.47 (1.41–1.52) | <0.0001 | 1.41 (1.36–1.46) | <0.0001 |
| Muscle relaxants | 1.40 (1.34–1.47) | <0.0001 | 1.29 (1.25–1.35) | <0.0001 |
| Tranquilizers | 1.29 (1.18–1.40) | <0.0001 | 1.24 (1.15–1.34) | <0.0001 |
| Antidepressants—other | 1.27 (1.21–1.33) | <0.0001 | 1.22 (1.16–1.27) | <0.0001 |
| Anti-Parkinson | 1.24 (1.15–1.35) | <0.0001 | 1.20 (1.11–1.29) | <0.0001 |
| Antidepressants—tricyclics | 1.09 (1.02–1.17) | 0.0119 | – | NS |
| Sedatives and sleep aids, excluding benzodiazepines | 1.05 (1.00–1.11) | 0.0376 | 1.08 (1.03–1.12) | 0.0010 |
| Mobility/frailty | ||||
| Wheelchair use | 1.79 (1.61–2.00) | <0.0001 | 1.80 (1.64–1.97) | <0.0001 |
| Mobility impairment | 1.46 (1.41–1.51) | <0.0001 | 1.39 (1.34–1.43) | <0.0001 |
| Home healthcare | 1.24 (1.16–1.34) | <0.0001 | 1.20 (1.13–1.28) | <0.0001 |
| Nursing home | 1.19 (1.12–1.28) | <0.0001 | 1.19 (1.13–1.26) | <0.0001 |
Risk factors with OR > 1 and significant (P < 0.05) included on table
CNS central nervous system, DCI Deyo-Charlson Comorbidity Index, NS nonsignificant, OR odds ratio, SSRI selective serotonin reuptake inhibitor
aReference group: 0